Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $44,612 | $42,326 | $69,908 |
| - Cash | $47,532 | $25,752 | $40,269 | $12,474 |
| + Debt | $15,127 | $17,917 | $17,920 | $18,025 |
| Enterprise Value | – | $36,777 | $19,977 | $75,459 |
| Revenue | $6,500 | $0 | $0 | $4,000 |
| % Growth | – | – | -100% | – |
| Gross Profit | $6,075 | $0 | $0 | $4,000 |
| % Margin | 93.5% | – | – | 100% |
| EBITDA | -$19,300 | -$31,761 | -$34,171 | -$33,342 |
| % Margin | -296.9% | – | – | -833.6% |
| Net Income | -$19,725 | -$31,231 | -$32,085 | -$28,731 |
| % Margin | -303.5% | – | – | -718.3% |
| EPS Diluted | -0.26 | -0.41 | -0.42 | -0.38 |
| % Growth | 36.6% | 2.4% | -10.5% | – |
| Operating Cash Flow | -$19,115 | -$26,075 | -$34,231 | -$20,744 |
| Capital Expenditures | $0 | -$20 | -$47 | -$53 |
| Free Cash Flow | -$19,115 | -$26,095 | -$34,278 | -$20,797 |